financetom
Business
financetom
/
Business
/
Datavault AI (DVLT) Stock Falls Friday After Major Shareholder Dumps 14.7M Shares
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Datavault AI (DVLT) Stock Falls Friday After Major Shareholder Dumps 14.7M Shares
Mar 11, 2026 12:12 AM

Datavault AI Inc. ( DVLT ) shares are down on Friday, pulling back following Thursday’s surge. Here’s what investors need to know.

Also Read: 11 Information Technology Stocks Moving In Friday’s Pre-Market Session

Major Shareholder Dumps 14.7M Shares

Datavault AI ( DVLT ) filed a Form 4 showing that Scilex Holding Co. sold a total of 14,713,490 DVLT common shares between Jan. 6–8, 2026 at prices around $1.07–$1.37, leaving it with about 229.7 million shares.

These transactions were reported as open-market sales, indicating a clear move to reduce Scilex's economic stake in the company rather than just an internal restructuring of holdings.

A large, visible sell-down by a major shareholder often spooks other investors and adds selling pressure to the market, so traders could interpret this as a bearish signal and push DVLT stock lower on Friday.

How Datavault’s Expansion Could Impact AI Adoption

The company this week revealed that it will deploy its SanQtum AI platform in New York and Philadelphia, utilizing International Business Machines Corporation ( IBM )‘s (NYSE:IBM) watsonx AI products to enhance data processing capabilities. This initiative aims to provide cybersecure data storage and real-time scoring, allowing clients to convert raw data into tradable digital assets instantly.

In addition, Datavault AI ( DVLT ) plans to implement its DVHOLO holographic displays and ADIO spatial audio technology in collaboration with Riflessi, a luxury retail destination in New York City, starting February 2026. This deployment is expected to create immersive advertising experiences and generate new revenue through customized content.

Read Next: 12 Information Technology Stocks Moving In Friday’s Intraday Session

Is DVLT Stock Set For A Rebound?

The stock is currently trading 11.1% below its 20-day simple moving average (SMA) and 29.2% below its 100-day SMA, indicating a bearish trend. Shares have decreased by 21.98% over the past 12 months and are positioned closer to their 52-week lows than highs.

The RSI is at 44.54, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is above its signal line, indicating potential bullish momentum.

The combination of neutral RSI and bullish MACD suggests mixed momentum.

Key Resistance: $1.00

Key Support: N/A

Earnings & Analyst Outlook

Investors are looking ahead to the next earnings report on March 30.

EPS Estimate: Loss of 9 cents (Up from $-2.00 YoY)

Revenue Estimate: $24.70 million (Up from $0.90 million YoY)

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $4.00. Recent analyst moves include:

Maxim Group: Buy (Raised Target to $4.00)

Maxim Group: Upgraded to Buy (Target $3.00)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Datavault AI Inc. ( DVLT ) Common Stock (DVLT), highlighting its strengths and weaknesses compared to the broader market:

Momentum: Weak (Score: 20/100) — The stock is underperforming relative to the market.

Quality: Weak (Score: 25/100) — The company shows signs of financial instability.

Value: Risk (Score: 4/100) — Trading at a steep premium relative to peers.

The Verdict: Datavault AI’a Benzinga Edge signal reveals significant challenges ahead. With weak momentum and quality scores, investors should approach with caution, particularly given the stock’s current valuation concerns.

Price Action

DVLT Price Action: Datavault AI ( DVLT ) shares were down 6.53% at $0.94 at the time of publication on Friday, according to Benzinga Pro data.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BofA Securities to Pay $5.6 Million in Resolution of DOJ Market Manipulation Probe
BofA Securities to Pay $5.6 Million in Resolution of DOJ Market Manipulation Probe
Sep 20, 2025
05:10 PM EDT, 09/18/2025 (MT Newswires) -- Bank of America Corp's ( BAC ) unit BofA Securities, Inc. has agreed to resolve a criminal investigation into alleged market manipulation by former employees under the Justice Department's corporate enforcement policy, the agency said Thursday. The DOJ said it declined to prosecute the firm, which will disgorge about $1.96 million and contribute...
FedEx Beats First-Quarter Estimates Amid Domestic Package Revenue Strength
FedEx Beats First-Quarter Estimates Amid Domestic Package Revenue Strength
Sep 20, 2025
05:05 PM EDT, 09/18/2025 (MT Newswires) -- FedEx's ( FDX ) fiscal first-quarter results rose more than expected, buoyed by domestic package revenue gains and cost reductions. Adjusted per-share earnings increased to $3.83 in the three months ended Aug. 31 from $3.60 a year earlier. The FactSet-polled consensus was for $3.61. Revenue climbed to $22.2 billion from $21.6 billion, compared...
Incyte Gets FDA Approval for Opzelura in Children Aged 2 to 11
Incyte Gets FDA Approval for Opzelura in Children Aged 2 to 11
Sep 20, 2025
05:07 PM EDT, 09/18/2025 (MT Newswires) -- Incyte ( INCY ) said late Thursday the US Food and Drug Administration has approved the use of Opzelura cream to treat mild to moderate atopic dermatitis in non-immunocompromised children aged 2 to 11. The milestone marks the third US approval for Opzelura, it said. ...
Moderna settles Alnylam patent lawsuits over COVID vaccine technology
Moderna settles Alnylam patent lawsuits over COVID vaccine technology
Sep 20, 2025
Sept 18 (Reuters) - Moderna ( MRNA ) has settled related lawsuits that accused it of misusing Alnylam Pharmaceuticals' ( ALNY ) patented technology in its COVID-19 vaccines, according to filings on Thursday in Delaware federal court. The companies told the court that they had resolved their dispute and asked to dismiss Alnylam's claims with prejudice, which means they cannot...
Copyright 2023-2026 - www.financetom.com All Rights Reserved